Last updated on 2020-10-08 by Bill Denney

Analysis of pharmacokinetic (PK) data is concerned with defining the relationship between the dosing regimen and the body's exposure to drug as indicated by the concentration time curve to determine a dose. To analyze PK data, there are three categories of packages within CRAN: noncompartmental analysis (NCA), modeling (typically using compartmental analysis), and reporting (typically for NCA). NCA is used as method of description of PK with minimal assumptions of the rates of distribution of the drug through the body. NCA is typically used to describe the PK of a drug in clinical studies with many samples per subject on the same and sequential days. The NCA packages are:

- ncappc
- Performs traditional NCA and simulation-based posterior predictive checks for a population PK model using NCA metrics. It targets summarizing data from model-fit or simulated sources.
- NonCompart
- Provides basic computational functions for NCA.
- PK
- Allows estimation of pharmacokinetic parameters using non-compartmental theory. Both complete sampling and sparse sampling designs are implemented. The package provides methods for hypothesis testing and confidence intervals related to superiority and equivalence.
- PKNCA
- Computes standard NCA parameters and summarizes them with the goal of taking in observed clinical data and providing summaries ready for study reports and regulatory submission.

- clinPK
- Calculates equations commonly used in clinical pharmacokinetics and clinical pharmacology, such as equations for dose individualization, compartmental pharmacokinetics, drug exposure, anthropomorphic calculations, clinical chemistry, and conversion of common clinical parameters. Where possible and relevant, it provides multiple published and peer-reviewed equations within the respective R function.
- cpk
- Provides simplified clinical pharmacokinetic functions for dose regimen design and modification at the point-of-care.
- dfpk
- Provides statistical methods involving PK measures for dose finding in Phase 1 clinical trials.
- mrgsolve
- Facilitates simulation from hierarchical, ordinary differential equation (ODE) based models typically employed in drug development.
- nmw
- Is a package to understand the algorithms of NONMEM.
- PKPDmodels
- Provides functions to evaluate common pharmacokinetic/pharmacodynamic models and their gradients.
- pmxTools
- Pharmacometric tools for common data analytical tasks; closed-form solutions for calculating concentrations at given times after dosing based on compartmental PK models (1-compartment, 2-compartment and 3-compartment, covering infusions, zero- and first-order absorption, and lag times, after single doses and at steady state, per Bertrand & Mentre (2008)); parametric simulation from NONMEM-generated parameter estimates and other output; and parsing, tabulating and plotting results generated by Perl-speaks-NONMEM (PsN).
- scaRabee
- Provides a framework for simulation and optimization of pharmacokinetic-pharmacodynamic models at the individual and population level.

- ncar
- Provides NCA for a report writer generating rtf and pdf output.
- pkr
- Generates NCA data sets compliant to CDISC and other pharmacokinetic functions for reviewer.
- PKreport
- Provides automatic pipeline for users to visualize data and models with an archive-oriented management tool for users to store, retrieve and modify figures and graph generation based on lattice and ggplot2.
- xpose
- Diagnostics for non-linear mixed-effects (population) models from 'NONMEM'. 'xpose' facilitates data import, creation of numerical run summary and provide 'ggplot2'-based graphics for data exploration and model diagnostics.

- caffsim
- Simulate plasma caffeine concentrations using population pharmacokinetic model described in Lee, Kim, Perera, McLachlan and Bae (2015)

- microsamplingDesign
- Find optimal microsampling designs for non-compartmental pharacokinetic analysis using a general simulation methodology. This methodology consist of (1) specifying a pharmacokinetic model including variability among animals; (2) generating possible sampling times; (3) evaluating performance of each time point choice on simulated data; (4) generating possible schemes given a time point choice and additional constraints and finally (5) evaluating scheme performance on simulated data. The default settings differ from the article of Barnett and others, in the default pharmacokinetic model used and the parameterization of variability among animals.
- PharmPow
- PharmPow contains functions performing power calculations for mixed (sparse/dense sampled) pharmacokinetic study designs. The input data for these functions is tailored for NONMEM .phi files.

4 years ago by Sungpil Han

Simulation of Plasma Caffeine Concentrations by Using Population Pharmacokinetic Model

2 years ago by Artemis Toumazi

Bayesian Dose-Finding Designs using Pharmacokinetics (PK) for Phase I Clinical Trials

a year ago by Adriaan Blommaert

Finding Optimal Microsampling Designs for Non-Compartmental Pharmacokinetic Analysis

3 years ago by Kyun-Seop Bae

Understanding Nonlinear Mixed Effects Modeling for Population Pharmacokinetics

7 years ago by Frank Kloprogge

Pharmacometric Power calculations for mixed study designs

7 years ago by Xiaoyong Sun

A reporting pipeline for checking population pharmacokinetic model assumption

7 years ago by Sebastien Bihorel

Optimization Toolkit for Pharmacokinetic-Pharmacodynamic Models